Safety Study of the VEGA UV-A System to Treat Keratoconus
Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus
Sponsor: Topcon Medical Systems, Inc.
Terminated
The sponsor terminated the study prior to data analysis for financial reasons.
Other terminated trials from Topcon Medical Systems, Inc.
More terminations from Topcon Medical Systems, Inc.
Listed as NCT01190306, this PHASE3 trial focuses on Keratoconus and remains terminated or withdrawn. Sponsored by Topcon Medical Systems, Inc., it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Topcon Medical Systems, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .